Crystallography

The 2023 WLA Prize Award Ceremony to be Held in Shanghai on Nov. 6

Retrieved on: 
Wednesday, November 1, 2023

The World Laureates Association Prize (WLA Prize) is an international science prize established in Shanghai, in 2021, initiated by the World Laureates Association (WLA),  managed by the WLA Foundation, and exclusively funded by HongShan.

Key Points: 
  • The World Laureates Association Prize (WLA Prize) is an international science prize established in Shanghai, in 2021, initiated by the World Laureates Association (WLA),  managed by the WLA Foundation, and exclusively funded by HongShan.
  • Each year, the WLA Prize is awarded in two categories: "Computer Science or Mathematics" and "Life Science or Medicine", with the total award for each Prize being RMB 10 million.
  • The 2023 WLA Prize in Computer Science or Mathematics recognizes two scientists: Arkadi Nemirovski, the John P. Hunter, Jr.
  • Continuing last year's tradition, the ceremony will be held at the Opening Ceremony of the 6th WLA Forum, an annual scientific event which also features WLA Prize related academic lectures and dialogues starting from Nov. 5.

The 6th WLA Forum Will Embark on New Journey in Shanghai

Retrieved on: 
Monday, October 30, 2023

The Award Ceremony of the 2023 WLA Prize will be held on November 6 at the opening ceremony of the 6th WLA Forum.

Key Points: 
  • The Award Ceremony of the 2023 WLA Prize will be held on November 6 at the opening ceremony of the 6th WLA Forum.
  • Under the annual theme "Science Leads Transformation," the 6th WLA Forum introduces several notable enhancements to its dynamic program – a new chairmanship to the WLA featured forums, such as the WLA Life Science Forum, WLA Intelligent Science Forum, WLA Zero Carbon Forum, WLA Young Scientists Forum, etc.
  • Additionally, a new academic lecture series, the WLA Frontier Lectures, featuring approximately 60 scholarly presentations that showcase cutting-edge research progress will be launched at the 6th WLA Forum.
  • The five laureates of the 2023 WLA Prize announced last month will attend the 6th WLA Forum in person.

Laureates of the 2023 WLA Prize Announced

Retrieved on: 
Thursday, September 14, 2023

Shanghai, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The World Laureates Association Prize (WLA Prize) unveils its 2023 laureates on Thursday, at a press conference held in Shanghai.

Key Points: 
  • Shanghai, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The World Laureates Association Prize (WLA Prize) unveils its 2023 laureates on Thursday, at a press conference held in Shanghai.
  • The 2023 WLA Prize in Computer Science or Mathematics recognizes two scientists: Arkadi Nemirovski, John P. Hunter, Jr.
  • The 2023 WLA Prize Award Ceremony is scheduled to take place in Shanghai on November 6, followed by a series of engaging sessions to celebrate the laureates' outstanding achievements.
  • The WLA Prize is an international science prize established in Shanghai, in 2021, initiated by the World Laureates Association (WLA), managed by the WLA Foundation, and exclusively funded by HongShan.

Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration

Retrieved on: 
Tuesday, April 18, 2023

SEOUL, South Korea and NOTTINGHAM, England, April 18, 2023 /PRNewswire/ -- Daewoong Pharmaceutical has entered a research collaboration with Sygnature Discovery to expand its global open innovation for novel drug development.

Key Points: 
  • On the 18th April, Daewoong Pharmaceutical (CEO Seng-ho Jeon and Lee Chang-jae) has announced a research collaboration with Sygnature Discovery (CEO Simon Hirst), a global integrated drug discovery company, to discover a novel small molecule to target autoimmune diseases.
  • Sygnature Discovery will provide its proprietary Fragment-Based Drug Discovery (FBDD) and virtual high throughput screening (vHTS) to accelerate Daewoong's novel drug discovery for autoimmune diseases.
  • Through this collaboration, Daewoong Pharmaceutical expects to broaden its drug discovery scope to the field of protein-protein interaction (PPI) as a part of next-generation drug discovery strategy.
  • Sygnature Discovery is an integrated drug discovery company established in 2004 to support early drug development and clinical trials.

CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability

Retrieved on: 
Wednesday, January 4, 2023

LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.

Key Points: 
  • Enhanced leadership team brings strong AI and drug discovery expertise and experience, reinforcing CHARM Therapeutics’ existing R&D capabilities
    LONDON – 4 January 2023 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research Company discovering and developing transformational medicines, today announces the expansion of its leadership team with a series of key appointments to strengthen its drug discovery and development, as well as operational management capabilities.
  • These appointments will support CHARM as it builds out of its research and development function to advance discoveries driven by its proprietary 3D deep-learning engine towards development.
  • CHARM Therapeutics raised $50 million in a Series A financing round announced in 2022, led by F-Prime Capital and OrbiMed, with General Catalyst and Khosla Ventures.
  • Gary D. Glick Ph.D., Executive Chair of CHARM Therapeutics, commented: “The exceptional people joining CHARM bring the perfect combination of skills, from immersion in AI, oncology and translational research to long experience in organizational leadership.

Rigaku to Install XtaLAB Synergy-ED Electron Diffractometer at ICIQ in Spain

Retrieved on: 
Friday, December 23, 2022

Rigaku, a leader in developing crystallography solutions, is proud to announce that they will be installing the first XtaLAB Synergy-ED electron diffractometer in Europe at the Institute of Chemical Research of Catalonia (ICIQ) after having won a competitive tender.

Key Points: 
  • Rigaku, a leader in developing crystallography solutions, is proud to announce that they will be installing the first XtaLAB Synergy-ED electron diffractometer in Europe at the Institute of Chemical Research of Catalonia (ICIQ) after having won a competitive tender.
  • This will be the first customer order of a dedicated electron diffractometer installed outside Japan.
  • (Photo: Business Wire)
    The Rigaku XtaLAB Synergy-ED is the world’s first turnkey electron diffractometer.
  • When asked about why the ICIQ team chose the Rigaku XtaLAB Synergy-ED, Dr. Eduardo C. Escudero-Adán, Manager of the Characterization Technologies Department at ICIQ, said, “We have tested the instrument in situ.

Fragment-Based Drug Discovery -- Hitting Targets Using the Right Chemistry and Expertise Alliances, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, September 26, 2022

TORONTO, Sept. 26, 2022 /PRNewswire-PRWeb/ -- Fragment Based Drug Discovery (FBDD) has become of increasing importance and interest in the past decade for hit finding and optimization. FBDD led to approved therapeutics and numerous drug candidates. It has empowered the industry to address targets that had previously been deemed "undruggable".

Key Points: 
  • The featured speakers will discuss innovations from fragment identification to lead optimization stage to identify preclinical drug candidates.
  • TORONTO, Sept.26, 2022 /PRNewswire-PRWeb/ -- Fragment Based Drug Discovery (FBDD) has become of increasing importance and interest in the past decade for hit finding and optimization.
  • Join this webinar to learn how fragment-based drug discovery solutions such as DRIVE-SM enable the identification, characterization, design and optimization of fragments into a preclinical drug candidate.
  • For more information, or to register for this event, visit Fragment-Based Drug Discovery Hitting Targets Using the Right Chemistry and Expertise Alliances.

Bruker Introduces Enabling New Scientific Capabilities for Cell Biology and Pathobiology Research with High-Field NMR Innovations

Retrieved on: 
Monday, August 22, 2022

The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.

Key Points: 
  • The new technology also facilitates cell biology research into highly dynamic intrinsically disordered proteins (IDPs) or protein regions that often play key roles in signaling pathways via phosphorylation, e.g.
  • It allows researchers to obtain essential information in crowded IDP spectral regions for the unambiguous assignment of IDP backbone resonances.
  • I am very excited to see which previously inaccessible but important scientific and pathobiology questions this innovative NMR technology can address.
  • Dr. Guido Pintacuda, CNRS Research Director and Director of the Lyon High-field NMR Center explained: The new Bruker 160 kHz MAS HCN probe will push structural, cellular and disease biology research into the next phase of the solid-state NMR scientific evolution.

Parse Biosciences Announces Partnership with Molecular Diagnostics Korea

Retrieved on: 
Monday, June 6, 2022

Parse Biosciences , a leading provider of scalable single-cell sequencing solutions, today announced a partnership with Molecular Diagnostics Korea (MDxK) that will expand its presence in Asia by providing its entire line of Evercode Whole Transcriptome products as well as Cell and Nuclei Fixation kits in South Korea.

Key Points: 
  • Parse Biosciences , a leading provider of scalable single-cell sequencing solutions, today announced a partnership with Molecular Diagnostics Korea (MDxK) that will expand its presence in Asia by providing its entire line of Evercode Whole Transcriptome products as well as Cell and Nuclei Fixation kits in South Korea.
  • The partnership comes shortly after the announcement of Parse Biosciences $41.5M Series B round in February 2022, which is enabling the company to expand commercialization of its single-cell RNA-Seq products in response to growing demand.
  • Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research.
  • At Parse Biosciences, we are providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease.

American Crystallographic Association (ACA) Summer Course in Chemical Crystallography

Retrieved on: 
Wednesday, January 19, 2022

WEST LAFAYETTE, Ind., Jan. 19, 2022 /PRNewswire-PRWeb/ --Improved Pharma is pleased to announce its sponsorship towards the 2022 ACA Summer Course in Crystallography to be held this summer at Purdue University.

Key Points: 
  • WEST LAFAYETTE, Ind., Jan. 19, 2022 /PRNewswire-PRWeb/ --Improved Pharma is pleased to announce its sponsorship towards the 2022 ACA Summer Course in Crystallography to be held this summer at Purdue University.
  • The course aim is to provide appropriate training on the theory as well as practical aspects of both Single Crystal Chemical Crystallography and X-Ray Powder Diffraction techniques for small molecules.
  • Understanding crystallography and its role in the pharmaceutical field continues to increase in importance as more molecules are characterized for their solid-state properties.
  • "In order to accelerate the development of life-saving drugs, it is critical to understand their solid-state properties," states Dr. Stephen Byrn, CSO of Improved Pharma.